Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 257

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 257
---
 2024 ESPP to be added on the first day of each January, starting      
 with January 1, 2024, by the lesser of (i) 10,198 shares of our common stock, (ii) 1% of the fully diluted shares of common stock       
 on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by our board. The number of      
 shares reserved under the 2023 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our       
 capitalization. As of January 8, 2025, the board of directors have granted an aggregate of 61,080 option awards under the 2024 Plan,    
 leaving 408,801 shares reserved for future issuance under the 2024 Plan.                                                                |

162 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS Certain Relationships and Transactions Other than the compensation agreements and other arrangements described under the sections entitled “ Executive Compensation” and “ Director Compensation” above and the transactions described below, since January 1, 2022, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which:

| ● | the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of our total asset amounts at December 31, 2022 and 2023); and                                                                                                   |
| ● | any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest. |

PBAX Relationships and Related Party Transactions Related Party Loans In order to finance transaction costs in connection with the Business Combination, the Sponsor or an affiliate of the Sponsor or certain of PBAX’s officers and directors may, but are not obligated to, to loan PBAX funds as may be required. On December 13, 2022, PBAX issued an unsecured promissory note in the principal amount of $1,500,000 (the “Promissory Note”) to the Sponsor, pursuant to which the Sponsor agreed to loan to the PBAX up to $1,500,000. On December 8, 2023, the Promissory Note was amended to increase the total principal amount to $1